Patent ID: 8906933

Claim:
A method of attenuating at least one deleterious symptom or effect of schizophrenia characterized by overstimulation of NK3 which comprises administering to a patient in need thereof a therapeutically effective amount of an NK3 receptor antagonist of formula I: wherein X is selected from the group consisting of aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl, each having 6 members or less in the ring; Y is selected from the group consisting of aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl; Z is selected from the group consisting of O, S and NR 7 ; R 1 , R 2 and R 7 are independently selected from the group consisting of hydrogen, and C 1 -C 6 alkyl; R 3 is selected from the group consisting of hydrogen, nitro, cyano, carboxyl, carbamoyl, methylsulfonamido, fluoro, chloro, bromo, hydroxy, methylsulfonyl, and methylsulfinyl, isoxazol-4-yl, C 1 -C 6 alkoxy, —C(NH)NHOH, sulfonic acid, and acetyl; R 4 is selected from the group consisting of hydrogen, hydroxy, methoxy, carboxyl, and tetrazol-5-yl; or optionally R 3 and R 4 , taken together can form a heterocycle; R 5 is selected from the group consisting of hydrogen, hydroxyl, carboxy, chloro, fluoro, cyano, —O(CH 2 ) 1-6 NMe 2 , C 1 -C 6 alkyl, —O(CH 2 ) 1-6 OCH 3 , —O(CH 2 ) 1-6 OH, acetyl, CF 3 , and C 1 -C 6 alkoxy; or optionally R 4 and R 5 , taken together can form a heterocycle; and R 6 is selected from the group consisting of hydrogen and hydroxyl.